UCB presented positive results from two Phase 3 studies (BE HEARD I and BE HEARD II) evaluating bimekizumab's efficacy and safety in treating moderate to severe hidradenitis suppurativa (HS) in adults.
The studies demonstrated statistically significant and clinically meaningful improvements in HS signs and symptoms at week 16, sustained through week 48. Some patients showed a rapid clinical response in terms of HiSCR50, which was achieved as early as week four after the first dose.
Two doses were evaluated, 320 mg biweekly and 320 mg every four weeks and a greater proportion of patients achieved HiSCR75 at week 16 versus placebo. A significant percentage of patients also achieved improved health-related quality of life in both doses across the Phase 3 trials.
UCB stated that bimekizumab, which inhibits IL-17A and IL-17F, has shown promising results in treating HS.
AbbVie has released the results of a study that assessed the 52-week efficacy and safety of Skyrizi (risankizumab) in patients with plaque psoriasis who had less response to IL-17 inhibitor therapy. The study demonstrated that treatment with Skyrizi was effective in reducing psoriasis signs and symptoms at week 16 and week 52, with no new safety signals observed.
The study included a difficult-to-treat patient population who had received at least six months of treatment with Cosentyx (secukinumab) or Taltz (ixekizumab) and had an inadequate response before switching to Skyrizi.
The primary endpoint was a reduction in signs and symptoms of psoriasis (sPGA 0/1) at week 16. The study found that over half of the patients (56.3%) achieved the primary endpoint at week 16, and the majority of patients (63.0%) achieved clear or almost clear skin (sPGA 0/1) at week 52. Additionally, 19.8% of patients achieved complete skin clearance at week 16, and 26.2% achieved complete skin response at week 52. 20.2% of patients at week 16 and 27.4% at week 52 achieved no symptoms such as pain, itching, redness, and burning.
Importantly, the study found no new safety signals, indicating that Skyrizi is a safe treatment option for patients with plaque psoriasis who have had an inadequate response to IL-17 inhibitor therapy.
Janssen presented new data showing that the initiation of Tremfya (guselkumab) had shown more remarkable treatment persistence compared to Cosentyx (secukinumab) or Taltz (ixekizumab) in moderate to severe plaque psoriasis patients based on real-world evidence.
The post-hoc analysis of the Phase 3 VOYAGE 2 trial showed improvement in clinical efficacy, itch relief, and quality of life improvements with Tremfya in patients with scalp psoriasis.
Real-world data analysis of the IBM MarketScan Research Databases from July 13, 2017, to May 1, 2021, revealed that Tremfya demonstrated more remarkable persistence in bio-naïve patients, as shown by longer median time to index treatment discontinuation, compared to secukinumab and ixekizumab.
The post-hoc analysis of the Phase 3 VOYAGE 2 clinical trial showed that Tremfya exhibited sustained clinical efficacy, reductions in mean Psoriasis Symptoms and Signs Diary (PSSD) itch scores, and improvements in the quality of life of adult patients with scalp psoriasis.
Regeneron and Sanofi shared findings from the clinical trial investigating the efficacy of Dupixent (dupilumab) in treating uncontrolled moderate-to-severe atopic hand and foot dermatitis in adults and adolescents.
The participants (n=133) were divided into two groups during the trial. The first group (n=67) received Dupixent every two weeks, adults given 300 mg and adolescents given either 200 mg or 300 mg based on their body weight, and the second group (n=66) received a placebo.
After 16 weeks, the results showed that patients treated with Dupixent experienced substantial improvements, including:
Primary Endpoint: 40% of patients achieved clear or almost clear skin on their hands and feet versus 17% in patients on a placebo
Key Secondary Endpoint: 52% of patients had itch reduction on their hands and feet, versus 14% in patients on a placebo